Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update ... company incurred in Q3 ...

Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

In this example, the acquisition of Morphic in August led to a $3.08 ... This is not a good time to buy Eli Lilly stock, but selling now probably isn't the right move either.

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... in Q3 that were primarily related to its acquisition of Morphic Holding. Without this acquisition, Lilly almost certainly wouldn ...